Christian-H. Heeger: Does the CHAMPION AF Trial Signal a Potential Paradigm Shift in Stroke Prevention for AF?
Christian-H. Heeger, Head of the Department of Rhythmology at Asklepios Hamburg Altona, Professor of Electrophysiology at University of Lübeck, shared on LinkedIn:
”New evidence in stroke prevention for atrial fibrillation – a potential paradigm shift?
The CHAMPION AF trial is the first large randomized study evaluating the WATCHMAN FLX™ system as a first-line therapy compared to direct oral anticoagulants (DOACs).
Why does this matter?
DOACs remain the standard of care for stroke prevention in non-valvular atrial fibrillation.
However, long-term bleeding risk continues to be a major clinical concern.
Study overview (CHAMPION-AF):
- Randomized controlled trial with ~3,000 patients worldwide
- Comparison: Left atrial appendage closure (LAAC) vs. DOAC therapy
- Multi-year follow-up
Primary endpoints:
- Stroke, cardiovascular death, and systemic embolism (non-inferiority)
- Non-procedural bleeding (superiority)
Study objective:
To demonstrate that a one-time interventional approach can provide a safe and effective long-term alternative to chronic anticoagulation – even in patients without contraindications to oral anticoagulants.
What could this mean for clinical practice?
If confirmed, these findings could significantly expand the role of LAAC—potentially positioning it as an earlier treatment option in stroke prevention strategies for atrial fibrillation.
A highly anticipated study with the potential to reshape treatment pathways.
With Option and Champion patients after or during PVI will also benefit from this strategy!”
Stay updated with Hemostasis Today.
-
Aug 21, 2026, 12:42Moustafa Abdou: Diagnosis and Management of Pyruvate Kinase Deficiency
-
Aug 21, 2026, 12:38Luluva Ghadiyali: Modern Approaches to Aplastic Anemia
-
Aug 21, 2026, 12:34Kellie Machlus: Animal Models Driving Progress in Thrombosis Research
-
Aug 21, 2026, 12:08Amy Allen Whitfield: Helping to Proceed Bleeding Disorders Care
-
Aug 21, 2026, 11:53Jan Terje Andersen: Harnessing Placental Biology for Therapeutic Engineering
-
Aug 21, 2026, 11:02Severe ITP, Critical Bleeding, and the Challenge of Platelet Testing – RPTH Journal
-
Aug 21, 2026, 10:46Arwa Z. Al-Riyami: Looking Ahead to ISBT Muscat 2029
-
Aug 21, 2026, 10:42Janine Mothershed: What Is Romiplostim and How Does It Work in Immune Thrombocytopenia?
-
Aug 21, 2026, 10:33Omar Alkharabsheh: Excited to Build the Future of Hematologic Malignancy Care in Central Florida